BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ
Tweet Content
BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off